ORA busy training new investigators
This article was originally published in The Silver Sheet
Executive Summary
FDA's Office of Regulatory Affairs (ORA) is training an influx of new investigators and adjusting to the retirement of some of its most experienced staffers. According to Michael Chappell, acting associate commissioner for regulatory affairs in ORA, the office has hired more than 700 new device, drug and other investigators, and 70 analysts since 2008. This means about 30 percent of ORA's investigators are new, Chappell said at a recent Food and Drug Law Institute meeting in Washington, D.C. "This creates some major training and mentoring challenges," he said. Nevertheless, Chappell reiterated the new administration's commitment to stronger enforcement at FDA. The agency is already issuing warning letters much faster following an inspection, he said. In the first half of fiscal year 2010, FDA issued 378 warning letters, while it issued only 473 during the entire fiscal year 2009, Chappell noted
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.